Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy.
Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy.
复制标题
欧洲研究和治疗癌症生活质量调查表Core 30和治疗癌症治疗之前和期间，患者的变化和最小临床上的临床差异很小。
DOI：
10.1186/1471-2407-13-165
复制
发表时间：
2013-03-28
期刊：
影响因子：
3.8
通讯作者：
Berry DL
中科院分区：
文献类型：
--
作者：
Hong F;Bosco JL;Bush N;Berry DL
健康相关生活质量（HRQOL）评分的临床解释具有挑战性。本分析的目的是解释评分变化，并确定欧洲癌症研究和治疗组织生活质量问卷-核心30 （QLQ-C30）在癌症治疗前（T1）和（T2）期间的最小临床重要差异（MCID）。两家综合癌症中心的干细胞移植（SCT）和医学（MED）或放射（RAD）肿瘤学患者（N = 627）参加了电子自我报告评估-癌症研究，并在T1和T2完成了QLQ-C30。在T2时使用受试者意义问卷（SSQ）报告身体（PF）、情绪（EF）、社会（SF）、认知功能（CF）和整体生活质量（QOL）这五个生活质量领域的感知变化。以SSQ评分表示“改善”、“相同”或“恶化”为基础，计算QLQ-C30评分变化的均值和效应大小。MCID采用两件套线性回归模型，计算为QLQ-C30评分变化反映SSQ评分类别变化的平均差值。大多数SCT患者（54%）认为整体HRQOL恶化（17%），而MED/RAD患者认为改善（25%）和恶化（26%）的比例大致相同。在SSQ中报告“相同”的患者中，总体生活质量分别下降14.2 （SCT）和2.0 （MED/RAD）个单位。在报告HRQOL恶化的患者中，MCID为5.7-11.4 （SCT）和7.2-11.8 （MED/RAD）单位；MED/RAD患者报告改善的范围为2.7-3.4个单位。除了总体生活质量（MCID =6.9）外，在报告改善的SCT患者中没有发现有意义的MCID。肿瘤治疗对SCT患者HRQOL的影响大于MED/RAD患者。QLQ-C30评分变化的MCID在不同领域存在差异，在感知改善和恶化方面存在差异，提示癌症治疗期间HRQOL自我评价的标准不同。具体来说，临床注意力可以集中在报告至少下降6分的患者，以及报告QLQ-C30域至少增加3分的患者。该试验已在ClinicalTrials.gov注册：NCT00852852
Clinical interpretation of health related quality of life (HRQOL) scores is challenging. The purpose of this analysis was to interpret score changes and identify minimal clinically important differences (MCID) on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) before (T1) and during (T2) cancer treatment. Patients (N = 627) in stem cell transplant (SCT) and medical (MED) or radiation (RAD) oncology at two comprehensive cancer centers, enrolled in the Electronic Self-Report Assessment-Cancer study and completed the QLQ-C30 at T1 and T2. Perceived changes in five QOL domains, physical (PF), emotional (EF), social (SF), cognitive functioning (CF) and global quality of life (QOL), were reported using the Subject Significance Questionnaire (SSQ) at T2. Anchored on SSQ ratings indicating “improvement”, “the same”, or “deterioration”, means and effect sizes were calculated for QLQ-C30 score changes. MCID was calculated as the mean difference in QLQ-C30 score changes reflecting one category change on SSQ rating, using a two-piece linear regression model. A majority of SCT patients (54%) perceived deteriorating global HRQOL versus improvement (17%), while approximately equal proportions of MED/RAD patients perceived improvement (25%) and deterioration (26%). Global QOL decreased 14.2 (SCT) and 2.0 (MED/RAD) units, respectively, among patients reporting “the same” in the SSQ. The MCID ranged 5.7-11.4 (SCT) and 7.2-11.8 (MED/RAD) units among patients reporting deteriorated HRQOL; ranged 2.7-3.4 units among MED/RAD patients reporting improvement. Excepting for the global QOL (MCID =6.9), no meaningful MCID was identified among SCT patients reporting improvement. Cancer treatment has greater impact on HRQOL among SCT patients than MED/RAD patients. The MCID for QLQ-C30 score change differed across domains, and differed for perceived improvement and deterioration, suggesting different standards for self-evaluating changes in HRQOL during cancer treatment. Specifically, clinical attention can be focused on patients who report at least a 6 point decrease, and for patients who report at least a 3 point increase on QLQ-C30 domains. The trial was registered with ClinicalTrials.gov: NCT00852852
登录
查看更多内容
影响因子：
3.1
作者：
Kvam, Ann Kristin;Fayers, Peter M.;Wisloff, Finn
通讯作者：
Wisloff, Finn
影响因子：
6.2
作者：
Ringash, Jolie;O'Sullivan, Brian;Redelmeier, Donald A.
通讯作者：
Redelmeier, Donald A.
DOI：
10.1093/jnci/85.5.365
发表时间：
1993-03-03
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
AARONSON, NK;AHMEDZAI, S;TAKEDA, F
通讯作者：
TAKEDA, F
影响因子：
3.5
作者：
King, MT
通讯作者：
King, MT
DOI：
10.1016/0197-2456(89)90005-6
发表时间：
1989-12-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
JAESCHKE, R;SINGER, J;GUYATT, GH
通讯作者：
GUYATT, GH